|Bid||143.07 x 200|
|Ask||143.11 x 100|
|Day's Range||142.20 - 143.88|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||62.04|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.